WINT · Windtree Therapeutics Inc /De/

Substantial doubt about the company's ability to continue as a going concern.

“We do *not* have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form *10*-Q to support our operations for at least the *12* months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern. To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to secure additional capital, potentially through a combination of public or private securities offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets; however, *none* of these alternatives are committed at this time.”

View the 10-Q filed Nov 19, 2025